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THE THERAPY OF ACUTE STAPHYLOCOCCAL
INFECTION OF MICE WITH ANTITOXIN
AND SULFONAMIDE COMPOUNDS*
MORRIS TAGER
Interest in the treatment of acute, systemic staphylococcal infec-
tions has been focused, in recent years, on the value of specific
antitoxin and of the drugs of the sulfonamide group. The chief
object of this study was to evaluate further the effectiveness of
antitoxin, sulfapyridine, sulfathiazole, and sulfamethylthiazole in
acute staphylococcal infection of mice.
Long and Bliss,20 and Mellon, Gross, and Cooper,24 in their mono-
graphs, have reviewed the conflicting evidence on the action of sulfanilamide,
neoprontosil, and other early derivatives which have not found satisfactory
clinical application. The reported experimental work on the action of sulfa-
pyridine, sulfathiazole, and sulfamethylthiazole has held out greater promise
of success against the staphylococcus. Whitby37 reported slight protective
action with sulfapyridine against staphylococcal infection in mice, but experi-
mental detail was omitted. Bliss and Long4 demonstrated a significant pro-
longation in the life of mice treated with sulfapyridine following intravenous
infection. Mayer23 similarly observed some action in a small group of mice
infected intraperitoneally, after they had been rendered more susceptible by
mucin. Barlow and Homburger2 infected mice intravenously with 800
million organisms, and found sulfathiazole and sulfamethylthiazole effective in
prolonging life and in preventing the development of internal abscesses or in
their healing. They further noted, in groups of 20 mice observed for 20
days, that sulfamethylthiazole was superior to sulfathiazole, and that both
were considerably more effective than sulfapyridine. Bliss and Ott,5 sub-
jecting mice to severe intravenous infection, found negligible survival in 30
days, but significant prolongation of survival time, with sulfapyridine, sulfa-
thiazole, and sulfamethylthiazole. The last two were equally effective and
superior to sulfapyridine. Rake and McKee,30 studying intraperitoneal in-
fection in mice rendered more susceptible by mucin, found, at the end of 31
days, little if any activity on the part of sulfapyridine, but definite protection
afforded by the thiazole compounds, with sulfathiazole superior to sulfa-
methylthiazole. Evidence of persistence of staphylococci in internal organs
was noted in 14 per cent of the sulfathiazole survivors and in 25 per cent of
the sulfamethylthiazole group.
* From the Department of Internal Medicine, Yale University School of
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Some clinical data have accumulated in support of the actiQn of these
compounds in severe staphylococcal infections. These, to date, have con-
sisted in reports of isolated cases. Success in clearing the blood stream and in
arresting the underlying process with sulfapyridine has been reported by Max-
well,22 O'Brien and McCarthy,28 Fenton and Hodgkiss," Abramson and
Flacks,' Goldberg and Sachs,"3 and others. Success in the clinical therapy
of staphylococcal sepsis with sulfamethylthiazole was first reported by Herrel
and Brown."5 The total number of reported cases is at present too small and
the period of follow-up observation as yet too brief to warrant a final opinion
as to the clinical effectiveness of these agents.
The question of the value of staphylococcal antitoxin in the treatment of
acute infections with this organism is intimately bound up with the problem
of the relative importance of the antitoxic, antibacterial, and, indeed, unknown
factors in staphylococcal immunity. It is further complicated by the mul-
tiplicity of toxic principles isolated from this organism, and the, as yet, unestab-
lished relative importance of these toxins in human infections. This problem
has recently been brought to the fore by such studies as those of Valentine85 86
on the significance of the antileukocidin response in severe staphylococcal
infections.
It is beyond the scope of this report to enter into discussion of these prob-
lems. The most convincing laboratory proof of the value of antitoxic serum
must be sought in experiments designed to test its ability to prolong life or
to protect completely the experimental animals. It is with this phase of the
problem that the present study is primarily concerned, since review of the
literature reveals that this aspect has received relatively limited consideration.
Burnet was among the first to note the ability of staphylococcal antitoxin
to prolong the life of rabbits infected intravenously, although all animals
ultimately succumbed. Connor and McKie8 protected completely a few
rabbits against similar infection, but no experimental detail was presented.
Bonnet, Thieffry, and Montefiore,6 likewise working with intravenous infec-
tion in rabbits, noted that 5 control animals died within 2 to 16 days; when
2500 units of antitoxin were administered 24 hours before the infection, 5
rabbits survived 3, 7, 14, 27, and 80 days, respectively. When the anti-
toxin was given simultaneously, two animals died in 3 and 27 days, respec-
tively; three were living at 60 days, and one at the end of 90. Parish,
O'Meara, and Clark29 had essentially similar experience with a few rabbits,
and observed some prolongation in the life of mice infected intraperitoneally.
Rigdon3' reinvestigated this problem in rabbits, testing the effect of a single
dose before infection, multiple doses after intravenous inoculation, and the
combination of these procedures. Although a marked prolongation of life
was achieved, the therapy did not avert the development of the internal
pyogenic foci. Nelis,26 on the other hand, failed to protect animals sig-
nificantly with antitoxin against infections with living staphylococci. In an
extensive study of staphylococcal immunity, Kitching and Farrell'8 noted a
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marked protective action on the part of antitoxin against intraperitoneal
staphylococcal infection in mice when the antitoxin was given 18 hours before
the infecting dose. However, their period of recorded observation was
limited to 24 hours, although they claim that animals surviving this long
are likely to live indefinitely.
While the number of animals used in most of the above reports has been
small, and adequate dosage of antitoxin perhaps not always administered, the
evidence certainly suggests that antitoxin exerts some protective action against
infections with living staphylococci.
Of some interest is the attempt of De and Basu9 to evaluate the com-
bined effect of sulfanilamide, antitoxin, and antibacterial serum in intraperi-
toneal staphylococcal infection in mice. A synergistic action was noted,
although the number of mice in each group was limited to 12, and the total
period of observation to only 4 days. Clinically, Meyer25 reported "cures"
in 3 apparently hopeless cases of severe staphylococcal sepsis complicating
prostatic abscess, osteomyelitis, and pelvic infection, respectively, when sulfanil-
amide and antitoxin therapy were combined. The hope of controlling infec-
tions by the combined use of immunological and chemotherapeutic agents
has been frequently expressed since the advent of the newer drugs, and has
already found application in other fields.
Methods
The organism employed was a hemolytic Staphylococcus aureus isolated
from the blood stream of a patient suffering from osteomyelitis. This strain,
named "T3," fermented mannite, coagulated rabbit plasma, and under
special conditions of growth, produced for human blood a leukocidin active in
a dilution of 1:25, and for rabbit blood a hemolysin active in a dilution of
1:50.* Its mouse virulence was increased by three intratesticular passages,
as suggested by Duran-Reynals.'0 In order to obtain effective concentra-
tions, the organisms were grown on infusion agar plates and incubated for
from 18 to 24 hours. At the end of this period, 5 to 10 cc. of infusion
broth were added to the plates, the organisms were brought into suspension
with a platinum loop, and the agar plates were re-incubated for an additional
3 to 6 hours. The bacterial counts were determined by the Hopkins
method."6 It was found that 4 to 5 billion organisms subcutaneously would
kill 80 to 100 per cent of the mice, but that any reduction in that dosage
would reduce the mortality rate sharply.
Adult, laboratory raised, infection-free mice of approximately 20 grams
weight were used throughout. Various strains were employed; in some experi-
ments a single strain was used, in others, where more than one strain was
used, they were evenly divided among the groups.
Preliminary studies with intracerebral, intraperitoneal, intrapulmonary,
and intranasal routes of inoculation led to acute infections with death in from
* Titrated by Miss Olive Durfee of the Lederle Laboratories, Inc.
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24 to 48 hours in a majority of the animals receiving the effective dose.
Attempts by these routes to produce an illness with a subacute course met
with failure. Reduction below the acutely lethal dose led to a sharp drop
in the mortality rate rather than to the establishment of a fatal, but more
chronic infection. Efforts to duplicate Hoyle's17 results in the production of
staphylococcal pneumonia by intranasal instillation under ether were unsuc-
cessful, possibly due to a difference in the strain of organism used. The sub-
cutaneous route was finally selected as perhaps representing a portal less
foreign to the staphylococcus than the other modes of inoculation, and one
which would lend itself to observation of the local lesion produced. All
inoculations were carried out in the anterior abdominal wall.
Powdered sulfapyridine, sulfathiazole, and sulfamethylthiazole were
administered subcutaneously in the form of a 5 per cent acacia-saline suspen-
sion, in concentrations of either 20 or 40 mg. per cc. While the concentra-
tion of these compounds was not determined in any of the experimental
animals, preliminary values were obtained on the pooled heart blood of three
mice for each determination of blood level. Free sulfapyridine levels were
determined on two sets of mice; in one set at intervals after a single dose of
20 mg., in the other after three doses of 20 mg. each, given at intervals of 5
hours (Table 1A). Free and total sulfathiazole levels were obtained at inter-
vals after a single dose of 20 mg. of sulfathiazole, and two levels after two
doses of 20 mg. each, given at an interval of 8 hours (Table 1B).
TABLE IA
BLOOD CONCENTRATION OF SULFAPYRIDINE (FREE), MG.%0o*
Time after injection (hrs.)
SP Dose 1 3 3.5 6 8 14.5 17 20 24 37.5 48 66 72
20 mg. 11.5 ... 12 7.5 4 ... 5.5 ... 3.8 ... 0.9 0.9 ...
20 mg. 3x
(at 0.5 andl1 ... 15 ... 14.5 ... 19 ... 11 ... 1.8 ... 1.8 1.1
hrs., resp.)
TABLE IB
BLOOD CONCENTRATION OF SULFATHIAZOLE, MG.S
Time after injection (hrs.)
Free Total
ST Dose 1 7.5 8 16 24 38 48 1 7.5 8 16 24 38 48
20mg. 10 5.. 3 1 ... 1.4 10.6 5.4 ... 3.2 1 ... 1.4
20 mg. 2x
(at 0 and 8hrs., ... ... 12 ... ... 2.0 ... ... 12.8 ... ... 2.0 ...
resp.)
* The blood determinations were made by Dr. James W. Haviland and Dr. Norris Brookens.THERAPY OF STAPHYLOCOCCAL INFECTION
It is noteworthy that adequate blood levels were attained by the intro-
duction of these drugs subcutaneously, and that with a repetition of doses as
indicated, a cumulative effect was produced, leading to higher blood con-
centration maintained for a longer period of time. It is therefore very likely
that in the experiments presented in Table 2, adequate blood levels were
maintained whenever more than one dose was administered in the course of
24 hours. Animals receiving the sulfonamide compounds only, in doses equal
to those used in the experiments, showed no evidence of intoxication.
Lederle Staphylococcus Antitoxin (Globulin Modified), containing
20,000 International Units of antilysin per vial, or approximately 900 to
1000 units per cc., and about 6 K Valentine units of antileukocidin,3 was
used exclusively.
The therapeutic agents were administered subcutaneously on the dorsal
aspect, without coming into direct contact with the infected area on the ven-
tral surface.
The control groups received, during the first 24 hours following infection,
an amount of fluid (saline or acacia-saline) equivalent to that of the treated
groups. The maximum volume of fluid administered in the course of therapy
was well tolerated by a fluid control group of 5 mice.
Experimental results
The results of therapy with antitoxin, sulfapyridine, sulfathia-
zole, and sulfamethylthiazole are summarized in Table 2.
Sulfapyridine alone. When a single dose of 20 mg. per day was
given (Exp. I) no significant protection was obtained. The admin-
istration of three doses of 20 mg. within the first 18 hours after
infection (Exp. II), followed by 20 mg. b.i.d. for three days and
then 20 mg. daily for three days, led to a notable increase in sur-
vivors during the first week, although ultimately most of these
animals succumbed. The most striking early protective action was
noted in Exp. III, when a 20 mg. dose was given half an hour
before the infecting dose, even though the next therapeutic dose was
withheld for 18 hours. This degree of protection during the first
week was not duplicated in any of the other experiments and might
have been influenced by the strain of mice used,-in this instance
the highly inbred "Strain A." In spite of the preliminary dose of
sulfapyridine given 2 hours before infection in Exp. IV, using, how-
ever, almost twice the infecting dose, a different strain of mice, and
smaller daily dosage of sulfapyridine, no striking early protection
was afforded.
The question of the effect of delayed therapy was then investi-
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No. Strain Staph. Total
Exp. Date Therapy mice mice dose daqj 1 2 3 4 5 6 7
I 3/ 2/39 SP. 20 ABC 5 40 8 8
Cont. 20 Albino Billion 12 2 1
II 7/15/39 SP. 85 Swiss 4.5 60 8 2 2 4
Cont. 35 Albino Billion 23 5 1
III 3/14/39 SP. 20 A 4.5 36 3 1 1
Cont. 20 Albino Billion 9 9 I
IV 4/ 7/39 SP. 20 Dilute 8 30 10 5 1 1
Cont. 20 Brown Billion 15 4
V 3/30/39 SP. I 2D Dilute 6 42 10 4 2
SP. II 20 Brown Billion 13 3 2 1
Cont. 20 10 6 2
VI 10/ 8/39 SP. I 25 ABC 6 40 4 9 3 2
SP. II 25 Albino Billion 5 5 2 3
Cant. 25 16 9
VII 4/24/39 AT+SP. 20 Dilute 5 48 2 1 2 1
AT. 20 Brown Billion 5 2 1 1
SP. 20 10 1 1
Cont. 20 12 7
VIII 5/ 8/39 AT+SP. 20 C-Bagg 5.5 45 1
AT. 20 Albino Billion 6 2 1
SP. 20 5 3
Cont. 20 8 7
IX 5/25/39 AT+SP. 20 Swiss 6.5 33 6 1 1 1 1
AT. 20 Albino Billion 7 4 2 1 2
SP. 20 13 1 1 1 1 1
Cont. 20 16 3 1
X 6/15/39 AT+SP. 50 ABC-AC 8 50 19 5 4 4 2
AT. 50 Albino Billion 28 6 1
SP. 50 47
Cont. 50 44 4 1 1
XI 2/28/40 MT. 25 ABC 6 75 1 5
Cont. 25 Albino Billion 5 7 1 1
XII 1/ 6/40 MT. 50 CCIH 6 100 3 1 2 1
Cont. 50 Brown Billion 24 8 1 2 2
XIII 3/20/40 S^P 59 Swiss 9 60 32 3 1 1
ST 50 + Billion 27 4 1 1 1
MT. 50 ABC 22 6 1 1 2 1
AT. 50 Albino 14 15 1 1
Cont. 50 44 4 1
XIV 5/22/40 AT. 50 Swiss 7 38 5 12 9 1 1 1
ST. 50 Albino Billion 32 6 3 1 1
AT+RT. 50 O"+H R 4 7 6 6 1
(,ont. 50 Brown 39 5 2
SP = SiAlfRpyridline.
ST = Sulfathiazole.
MT = Sulfamethylthiazole.
AT = Staphylococcus Antitoxin, Lederle (Globulin Modified).
Exp. I. (3P. 20 mg. per 24 hrs., 1st dose immediately after infection.
Exp. II, SP. All doses 20 mg. 1st 3 doses at 1, 10, and 18 hrs. after infection. SubsequentlY b.i.d.
at 12-hour intervals for 3 days and single dose per 24 hrs. for 3 further days.
Exp. III, SP. 20 mg. at % hr. before infection, 18 hrs. after infection, followed by 5 doses at 8-hour
intervals and 1 dose per 24 hrs. until 13 days after infection.
Exp. IV, SP. 20 mg. 2 hrs. before infection and 3 and 8 hrs. after infection, followed by one dose
per 24 hrs. for 3 days.
Exp. V, SP. Group I: 20 mg. at 5 min. and 6 hrs. after infection. Subsequently b.i.d. at 12-hour
intervals for 4 days.
Grouip II: 1st dose 6 hrs. aftebr infection; otherwise as in Group I.
Exp. VI,SP. Group I: 20 mg. at 2 hrs., 6 hrs., and 11 hrs. after infection. Subsequently 20 mg.
t.i.d. at 8-hour intervals for 2 days and then 20 mg. per 24 hrs. until the 12th day.
Group II: 1st dose 6 hrs. after infection; otherwise as in Group I.
Exp. VII, SP1 and AT.
AT = 1 cc. 3% hrs. before infection.
SP 20 mg. at 1%, 131, and 25% brs. after infection. Then 20 mg. per 24 hrs. for 5
days and 10 mg. per 24 hrs. for 4 days until 10th day after infection.TABLE 2 (Cont'd.)
Deaths in dais %-~ 5Survival %
8 9 10 11 12 13 14 15-20 20-30 30-40 48 hr8. 7 days Ultimate
I 1 20 20 10
2 2 30 25 5
1 3 3 3 77 64 25
1 1 20 17 13
1 1 1 7 2 80 75 15
10 10 5
2 25 15 5
1 5 5 0
1 50 20 15
20 5 5
1 1 220 10 0
1 2 48 28 16
2 1 1 1 60 40 20
0 0 0
1 1 90 70 60
1 65 55 50
3 1 1 1 45 40 10
5 5 5
1 1 1 1 2 90 90 65
60 55 55
1 60 60 55
1 25 25 20
65 50 50
45 20 20
30 10 10
5 0 0
1 52 32 30
1 32 30 28
6 6 6
4 0 0
1 2 76 76 64
1 1 1 62 44 82
1 1 4 92 86 74
1 1 1 36 26 20
1 1 30 go 22
1 1 1 38 32 24
1 3 44 34 26
1 1 3 1 42 38 26
4 2 2
1 66 42 40
1 24 14 12 1 2 2 76 36 26 1 1 1 12 8 2
Exp. VIII, SP and AT.
AT = 1 cc. 2 hrs. after infection.
SP = 20 mg. at 4 hrs., 12 hrs., and 24 hrs. after infection. Subsequently 20 mg. per day
for 10 days, with dose reduced to 10 mg. on 6th, 7th, and 8th days.
Exp. IX, SP and AT.
AT = 1 cc. 2 hrs. after infaetion.
SP = 3% hrs., 12 hrs., and 24 hrs. after infection (20 mg.), then 20 mg. per 24 hrs. until
12th day after infection.
Exp. X, SP and AT.
AT = 1 cc. 2 hrs. after infection.
SP = 10 mg. at 3 and 8 hrs. after infection, 20 mg. 12 hrs. after infection, then 10 mg.
t.i.d. and 20 mg. b.i.d. for 2 following days. Then 20 mg. per 24 hrs. for 4 days
until after 7th day after infection.
Exp. XI, MT. All doses 10 mg. 1st dose % hr. after infection. Subsequently 7 doses q. 8 hra.
followed by 1 dose q. 12 hrs. through the 7th day after infection.
Exp. XII, MT. Each dose 20 mg.; otherwise as in Exp. XI.
Exp. XIII, SP., ST., MT., AT.
Drugs as in Exp. XII; 1st dose 2% hr.. after infection.
AT., 0.8 cc. 1% hr.. after infection.
Exp. XIV, ST., AT., ST.+AT.
ST. as in Exp. XII; let dose 21 hr.. after infection.
AT., 0.8 cc. 4 hr.. after infection.YALE JOURNAL OF BIOLOGY AND MEDICINE
gated. Accordingly, in Exps. V and VI, one group of mice did not
receive the first dose ofsulfapyridine until 6 hours after the infecting
dose, while the other group in each experiment received an earlier
dose 5 minutes and 2 hours respectively, after the infection. No
significant difference in ultimate survival was noted.
Further experience with sulfapyridine is provided by Exps.
VII, X, and XIII. These require no further comment, except to
point out that the failure of sulfapyridine alone to exert any action
in Exp. X may have been due tothe high infecting dose in a younger
group of mice, and the reduction in the daily sulfapyridine dose to
a level which, however, has been found adequate for the control of
intraperitoneal pneumococcal infection in mice.'4
Sulfamethyithiazole and sulfathiazole. The therapeutic results
with the thiazole derivatives are presented in Exps. XI to XIV.
Throughout the duration of Exp. XII, sulfamethylthiazole exerted
a highly significant degree of protection, and even the reduction of
each therapeutic dose to 10 mg. (Exp. XI) still left it some favor-
able action. In Exp. XIII, in which a higher infecting dose was
used,thetherapeutic result was considerably diminished, though still
significant. Sulfathiazole (Exp. XIII) exerted essentially the same
action as the other therapeutic agents, but its effectiveness was of a
lower order in Exp. XIV despite a reduction in the infecting dose.
Antitoxin alone. Preliminary titrations were carried out with
Lederle Staphylococcus Antitoxin (Globulin Modified) on a group
of 200 mice. These failed to demonstrate any significant protective
action against 6 to 10 billion organisms subcutaneously when less
than 0.5 cc. (about 500 International Units) was administered sub-
cutaneously or intraperitoneally. Some prolongation of life was
noted when 0.5 cc. were used. Intraperitoneal administration of
antitoxin was abandoned in preference to the subcutaneous route,
since the formerwas very irritating to the mouse and led to a marked
hyperkinetic response. A dose of 0.8 cc. or of 1 cc. was therefore
used. However, the latter dose is close to the toxic dose, especially
for a mouse less than 20 gm. in weight. Severe early reactions have
been observed, consisting in rigor, weakness, and, rarely, paraplegia
and rapid death.
The results of antitoxin therapy are presented in Exps. VII, X,
XIII, and XIV. The significance of these findings statistically in
terms of 48-hour, 7-day, and ultimate survival, is presented else-
where (Table 5). It is of interest here to point out the superiority
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of antitoxin over the chemotherapeutic agents during the first 24
hours after infection. This may be illustrated by Exp. XIV
(Table 3).
TABLE 3
EXPERIMENT XIV
Therapy No. of mice Mice dying after infection, at hours % survivors at 24 hrs.
6 9 10 24
ST. 50 3 3 17 9 36
AT. 50 1 0 2 2 90
AT.+ST. 50 3 2 1 2 84
CONTR. 50 3 4 17 15 22
This effect has constituted the most striking difference between
the action of the antitoxin and the drugs of the sulfonamide group.
A small number of animals are overwhelmed within 3 to 9 hours
after infection regardless of therapy, and the differences due to
therapy do not manifest themselves until after 12 hours following
infection.
Antitoxin plus sulfapyridine. In Exps. VII to X are sum-
marized the results with combined antitoxin and sulfapyridine
therapy. It appears that this form of therapy afforded maximum
protection against acute death (48 hrs.) when compared to the
effect of these agents separately, although the ultimate protection
was not significantly superior to antitoxin alone. The relatively
poor results of Exp. X, when compared to those of the three pre-
ceding ones, may again be attributed to the smaller sulfapyridine
doses, the larger infecting dose, and the fact that the mice used,
being smaller, may have been more susceptible to the toxic action of
the antitoxin.
Antitoxin plus sulfathiazole. The results of combined antitoxin
and sulfathiazole therapy are presented in Exp. XIV. Although
this proved superior to antitoxin and sulfathiazole alone during the
acute phase, it lost this advantage ultimately, with the final protec-
tion not significantly different from that of antitoxin, and not statis-
tically superior to sulfathiazole alone.
245246 YALE JOURNAL OF BIOLOGY AND MEDICINE
The results of Exps. I to XIV are summarized in Table 4.
TABLE 4
% survivor8
Therapy No. of mice 48 hrs. 7 days Ultimate
SP. 845 39 29 17
ST. 100 31 23 18
MT. 125 69 63 52
AT. 210 49 43 33
AT.+SP. 110 69 54 45
AT.+ST. 50 76 36 26
CONT. 425 16 11 7
These findings were submitted to statistical analysis by the "Chi
Square" test. The results are presented in Table 5.
TABLE 5
48 hrs. 7 days Ultimate
SP. and CONT ...................................................
ST. and CONT ...................................................
MT. and CONT ...................................................
AT. and CONT ...................................................
SP.+AT. and CONT. ............................................
ST.+AT. and CONT .............................................
AT. and SP.......................................................
AT. and ST.......................................................
MT. and AT......................................................
SP.+AT. and AT.................................................
ST.+AT. and AT................................................
SP.+AT. and SP.................................................
ST.+AT. and SP.................................................
SP.+AT. and MT. ..............................................
MT. and ST.+AT...............................................
SP.+AT. and ST................................................
ST.+AT. and ST................................................
SP.+AT. and ST.+AT...........................................
SP. and ST.......................................................
MT. and .P......................................................
MT. and ST.......................................................
+-Statistically significant difference.
a -Doubtfully significant difference.
O -Difference of no significance.
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
+ +
+ + +
+ + +
+ 0
+ 0 0
+ + +
+ 0 +
0 0 0
0 0 +
+ + +
+ 0 0
+ + +
+ + +THERAPY OF STAPHYLOCOCCAL INFECTION.
From these data, the following chief conclusions may be drawn:
Sulfapyridine, sulfathiazole, sulfamethylthiazole, and staphylococcal
antitoxin, as well as the combined use of antitoxin with sulfapyridine
and sulfathiazole respectively, afforded statistically significant pro-
tection throughout the duration of the experiment when compared
to the control group. Antitoxin proved superior to sulfapyridine
and sulfathiazole but did not surpass sulfamethylthiazole. Sulfa-
pyridine and sulfathiazole presented essentially the same order of
activity.
The combined use of sulfapyridine and antitoxin was superior to
sulfapyridine alone throughout, but definitely surpassed antitoxin
only during the acute phase. Sulfathiazole and antitoxin therapy
combined was superior to these agents alone only during the acute
phase.
Discussion
Subcutaneous infection with large doses of staphylococci in mice
leads to local and general effects. At the site of inoculation there
appear the phenomena of congestion, induration, necrosis, ulceration,
suppuration, and finally, healing by scar formation. The degree of
involvement is quite variable, and may extend over the entire
abdominal and thoracic wall. Likewise, the rate at which these
processes develop varies markedly from animal to animal, although,
in general, ulceration does not appear until some 7 days after infec-
tion. At death, inspissated purulent material may be found extend-
ing a considerable distance beyond the boundaries of the ulcer.
Rarely, an ulcer may perforate into the peritoneal cavity. In sur-
viving animals, healing by fibrosis is usually complete within 30
days, leaving only an uninfected scar.
Death within 24 to 48 hours is the most constant general effect
of an adequate dose ofvirulent staphylococci. As previously demon-
strated (Table 3) a small number of mice are overwhelmed within
a few hours of inoculation. Although the heart blood and organs
have been found consistently positive for staphylococci in animals
dying within 48 hours of inoculation, no gross pathology has been
noted at this time. The more chronic manifestations, as observed in
treated and in occasional untreated animals not dying acutely, con-
sisted mainly in renal abscesses, splenomegaly, and areas of pul-
monary congestion or consolidation, with or without pleural effusion.
Rarely, myocardial abscesses have been noted. These findings have
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been confirmed by microscopic sections. No gross involvement of
the vertebral column or of the brain has been observed in animals
developing hind-limb paralysis.
The occurrence of paralysis of the hind limbs deserves special
consideration. It has been observed to a slight extent in the control
groups receiving staphylococci only, but has been most striking in
the animals whose life has been prolonged by chemotherapy, less so
in the groups receiving antitoxin alone. Most of the animals devel-
oping anymarked degree ofthis disturbance succumb to the infection.
Uninfected mice receiving only the therapeutic agents failed to
develop this sign. Nelis26 has produced hind-limb paralysis in
experimental animals by the inoculation of staphylococcus toxin into
the femoral artery, and has neutralized this effect by specific anti-
toxin. It may be suggested, therefore, that the in vivo liberation of
toxin may account for the behavior of the different experimental
groups. The control groups succumb too acutely to manifest it
except to a minimal extent, and the surviving animals may be
regarded as possessing a high order of natural immunity which pro-
tects against any of the general manifestations of staphylococcal
infection. The mice treated with the chemotherapeutic agents are
probably not protected against any toxic action of the staphylococcus,
and while life is prolonged or saved by some other mechanism, the
liberation of toxin in vivo is given an opportunity to proceed
unchecked in some of the animals. Mice receiving antitoxin, on the
other hand, have this toxic action neutralized in part, and hence the
paralysis is inhibited, though not completely averted in all of the
animals. This phenomenon, however, requires further investiga-
tion, since no direct proof is as yet available as to its cause.
Those animals, treated and untreated, which succumbed to the
infection were found to harbor the organism in the blood stream;
failure to isolate staphylococci at death was rare. At the conclusion
of Exps. VII and VIII, cultures were made from the heart blood,
kidney, and spleen of all surviving mice, and no evidence of persist-
ing infection was found. Similarly, at the conclusion of Exps. XII
and XIII, selected mice were autopsied and cultured, as above, but
no pyogenic foci were demonstrated. However, the possibility of a
microscopic focus somewhere cannot be entirely excluded, since, as
Forssman"2 has pointed out, osteomyelitis of the vertebral column
may not become manifest until as late as a year following intravenous
infection of rabbits with staphylococci. Whenever surviving animals
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were killed and autopsied at the termination of the experiments, no
gross foci were noted.
Analysis of the experiments presented in Table 2 reveals a
marked degree of variation in the results obtained on different occa-
sions with the same therapeutic agent. Doubtless, factors such as
the nature and mode of therapy, the dosage of the staphylococcus
and its age, the strain and weight of the mice, as well as other influ-
ences whose operation is not established, have contributed to this
fact. It serves to re-emphasize the need of adequate numbers of
experimental animals before reaching conclusions with regard to the
action of the agents investigated.
Although the total results summarized in Table 5 point to a
statistically significant effectiveness on the part of all agents tested,
the degree of protection has fallen considerably short of that reported
for chemotherapeutic agents with such organisms as pneumococci and
streptococci. The relative lack of virulence of the staphylococcus
for the mouse and the consequent necessity of using a large dose to
produce a lethal infection may well have contributed to the appar-
ently reduced efficacy of the agents here tested, since it has been
shown that the effectiveness of sulfonamide compounds may vary
directly with the virulence and dosage of a susceptible organism.20' 27
The interpretation of animal experiments in terms of human
infection is always subject to limitations, and particularly is this true
here. In the first place, the type of infection produced in the mouse
in the present study simulates primarily the acute, fulminating type
of disease to which man may succumb even before the appearance of
pyogenic foci, and cannot be interpreted as casting any light on the
possible action of these agents in the chronic type of infection. A
further factor which must be weighed is the well-known natural
immunity of the mouse to staphylococci, since this may determine
ultimate survival of the resistant animal and yet be inoperative in
the relatively susceptible human subject. Consequently, one should
not translate directly the degree of protection demonstrated under
experimental conditions in terms of possible degree of effectiveness
in acute staphylococcal infection in the human subject, since it is not
possible to estimate to what extent the protective action of the agents
employed may prolong the life and materially influence the ultimate
prognosis in the human host. It is, perhaps, sufficient that these
agents afforded statistically significant protection, even though its
absolute degree was disappointing.
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It is beyond the scope of this study to enter into the controversy
of antitoxin versus antibacterial immunity in staphylococcal infec-
tion. The fact that both antitoxin and the chemotherapeutic agents
have afforded statisticallysignificant protection against staphylococcal
infection indirectly argues in favor of both mechanisms playing a
role. Most current investigations deny", 20 to the chemotherapeutic
agents any ability to neutralize exotoxins. Such studies as those of
Rigdon,33 who failed to protect with sulfapyridine rabbits inoculated
with staphylococcal toxin, lends further support to this view. One
nmight, therefore, infer that any action of these compounds is not
antitoxic but probably antibacterial.
Rigdon32 has demonstrated, in a study of subcutaneous staphylo-
coccal infection in mice, that the pathological changes produced are
identical with those caused by the injection of staphylococcal exo-
toxin, and are inhibited by antitoxin. One must note, however, that
with the doses used in the present study the factor of bacterial inva-
sion cannot be overlooked. Thus, when 5 billion organisms were
inoculated subcutaneously, and the animals were sacrificed at one-
half hour, one hour, and two hours respectively, all cultures of the
heart blood, spleen, and kidneys revealed an abundant growth of
staphylococci. However, the ability of antitoxin to save many ani-
mals from acute death, and to protect a smaller number indefinitely,
favors the view that the toxin plays a vital role in the pathogenicity
of the staphylococcus. One should emphasize, however, that the
present available antitoxin has a potent antilysin titer, antileukocidin
in high concentration, and perhaps other as yet unidentified fractions.
While the protection afforded by this product, within the limits of
the experiments presented, seems definite, it cannot be attributed to
the antilysin content without exploring the possible role of the
other principles.
Neither the antitoxin nor the chemical agents were able to avert
the development of lesions at the site of inoculation in the subcu-
taneous tissues. Likewise, internal pyogenic foci were not infre-
quently noted in treated animals succumbing to the infection. With
regard to the local lesion, no conclusion may be drawn as to the pos-
sible modifying effect of therapy when compared to the controls,
since the majority of the untreated mice succumb before a lesion
fully develops at the site ofinoculation.
It should be noted that all experiments presented in this study
were carried out with but one strain of staphylococcus. Such studies
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as those of Spink34 and Rigdon33 on the action of sulfanilamide and
sulfapyridine on different strains of the staphylococcus in vitro, as
well as the report of MacLean, Rogers, and Fleming2' on the dif-
ferent action of sulfapyridine in vivo and in vitro against various
strains of pneumococci, raise the possibility that other strains might
be affected differently by the therapeutic agents tested.
Summary
Studies are presented on the nature and therapy of acute sub-
cutaneous infection of mice with a single strain of hemolytic Staphy-
lococcus aureus.
Staphylococcus antitoxin (Globulin Modified), sulfapyridine,
sulfathiazole, and sulfamethylthiazole, all led to statistically signifi-
cant protection.
A single early dose of antitoxin proved superior to sulfa-
pyridine and sulfathiazole, but did not surpass the activity of
sulfamethylthiazole.
The combined use of sulfapyridine and antitoxin was superior to
sulfapyridine alone, but exceeded the activity of antitoxin definitely
only during the acute phase.
Combined sulfathiazole and antitoxin therapy was superior to
these agents separately only during the acute phase.
The best ultimate results were obtained by the combined use of
sulfapyridine and antitoxin, and by sulfamethylthiazole.
The limitations ofthe experimental methods used are presented.
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